What Artis Ventures does

Artis Ventures is a private venture capital firm founded in 2001 and headquartered at 499 Jackson Street in San Francisco. The firm invests at the intersection of technology and life sciences (its "TechBio" thesis), backing early-stage companies across AI-driven healthcare, biotech platforms, medical devices, digital health, and microbiome science. With 11-50 employees and a small partner group led by Founder and Managing General Partner Stuart Peterson, Managing Partner Vasudev Bailey, and Partner Omair Khan, the firm combines a 25-year track record with deep scientific judgment sourced through its Fellows Program (PhDs, MDs, and postdocs) and its AI Health Alliance of leading hospital systems.

The firm's "products" are its portfolio companies, each operating independently: Rad AI (generative AI radiology serving one-third of US health systems and 9 of 10 largest US radiology practices), Seed Health (microbiome science, Target's fastest-growing probiotics brand at 500%+ revenue growth over three years), Conceivable Life Sciences (AI-powered automated IVF platform that produced the first fully automated ICSI birth), ONTO Health (incubated fertility/longevity provider), Metriport (open universal API for patient medical data), Science (medical device/consumer electronics blending, founded by Neuralink co-founder Max Hodak), Luminate (at-home cancer infusion, expanding to 40 partner oncology clinics), Unnatural Products (macrocyclic peptide therapeutics with a Novartis license worth up to $1.7B in milestones), and Cartography Biosciences (antibody-based cancer therapies, backed in part by Pfizer Ventures). Historical exits include YouTube (acquired by Google in 2006), Stemcentrx (acquired by AbbVie in 2016), and Palantir (IPO in 2020).

The business model is venture capital returns: the firm deploys capital into early-stage equity rounds, leads or co-leads financings, and earns returns through IPOs, acquisitions, and secondary transactions when portfolio companies exit. Revenue is not publicly disclosed. Deal sourcing flows through direct founder outreach, the Fellows Program, the AI Health Alliance, and the firm's community of pharma executives, biotech founders, investors, and regulators. Notable 2024-2026 activity includes participation or co-lead roles in financing rounds totaling over $200M across multiple portfolio companies.

Name

Artis Ventures

Legal name

Artis Ventures

Website

https://av.co

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

11–50 employees

Short description

Artis Ventures is a San Francisco-based venture capital firm founded in 2001 that invests in early-stage TechBio companies at the intersection of technology and life sciences, backing founders in AI-driven healthcare, biotech, medical devices, and microbiome science through capital, clinical network access, and a Fellows Program.

Ownership category

akta.pro rank

Product category

Technology Venture Capital

NAICS

All Other Financial Investment Activities (52399)

SIC

Investors, Nec (6799)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

Keywords

• Venture capital funding
• Techbio equity investing
• Healthcare startup investment
• Biotech venture capital
• Early stage technology investment

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Venture Capital Returns: ARTIS generates returns through equity ownership in portfolio companies. Returns are realized through IPOs, acquisitions, and secondary transactions when portfolio companies exit. Notable exits include YouTube (acquired by Google), Stemcentrx (acquired by AbbVie), and Palantir (IPO).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Artis Ventures is a venture capital firm that invests equity capital in early-stage companies at the intersection of technology and life sciences (TechBio). It provides portfolio companies with capital investment, strategic partnership, operational support, and access to a curated network of hospital systems (AI Health Alliance), pharma executives, and scientific talent through the Fellows Program.

Product overview

Artis Ventures is a venture capital firm that does not offer a unified product or platform. Instead, it provides venture capital funding, strategic partnership, and operational support to visionary founders building companies at the intersection of technology and life sciences (TechBio). The firm's portfolio consists of distinct portfolio company brands spanning healthcare AI, data platforms, microbiome science, fertility technology, oncology, and consumer health. These portfolio companies operate independently and each offers its own distinct products and services.

Differentiator

Problem solved

Functional benefit

Brands

• TechBio: ARTIS's investment thesis focusing on the convergence of computer science and life science at the intersection of technology and biology.
• ARTIS Fellows Program
• ARTIS AI Health Alliance

Products and services

• Venture Capital Investment

Quantifiable outcome

• Multiple successful exits including YouTube ($1.65B Google acquisition 2006), Stemcentrx (AbbVie acquisition), and Palantir (IPO 2020)
• +1 more outcomes

Named customers6 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered supporting and core.

• Mount Sinai Icahn School of MedicinesupportingStrategic or Co-development Partner · 7 January 2026OncoAssure, a portfolio-related company, signed research collaboration with Mount Sinai's Icahn School of Medicine in New York to validate its prostate cancer test. Illustrates ARTIS network connections with leading academic medical centers.
• AI Health Alliance (Hospital Network)coreStrategic or Co-development Partner · 1 January 2024AI Health Alliance is a curated network of leading hospital systems partnering with ARTIS to shape the future of healthcare innovation. The network connects portfolio companies with healthcare systems for pilot programs, clinical validation, and market access.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Khosla Ventures: TechBio-focused VC investing aggressively at the intersection of AI and healthcare/biotech. Directly comparable to ARTIS—Khosla even led Rad AI's $50M Series B in which ARTIS participated—making it the closest head-to-head peer for both deal flow and growth-stage rounds.
• Lux Capital: Frontier-tech and science VC investing in 'bold, sciencеe- and technology-driven' companies across AI, biology, and healthcare. Directly comparable to ARTIS's TechBio thesis with a similar specialization in transformative, high-conviction bets.
• Andreessen Horowitz (a16z Bio): Large generalist firm with a dedicated Bio + Health fund investing across digital health, biotech, and AI × biology. Comparable to ARTIS in thesis area but with substantially more capital and broader sector coverage.
• DCVC (DCVC Bio): Deep-tech VC with an explicit computational biology practice (DCVC Bio). Directly comparable to ARTIS for AI/biology convergence bets and competing for similar early-stage TechBio deal flow.
• ARCH Venture Partners: Long-tenured biotech and frontier-science investor backing companies from inception through commercialization. Comparable to ARTIS in life-sciences orientation, though ARCH leans earlier-stage and biotech-dominant versus ARTIS's AI/bio hybrid.
• Section 32: Venture firm founded by Bill Maris specifically focused on health tech, biotech, and AI-driven medicine. Closely comparable to ARTIS in sector focus and stage, competing for similar healthcare AI founders.

Broad incumbents

• Founders Fund: Large, established tech VC with a frontier-tech thesis. Less specialized in TechBio than ARTIS but overlapping in tech/biology frontier bets; ARTIS was an early investor in Founders Fund-backed Palantir, illustrating historical overlap.

Emerging players

• 8VC: Tech-focused firm building companies at the frontier of AI, logistics, and bio. Comparable to ARTIS in frontier-thesis orientation and portfolio-construction style, though with a wider tech remit beyond healthcare.
• Obvious Ventures: Mission-driven VC backing founders addressing world-scale problems in health, sustainability, and technology. Partially overlapping with ARTIS in health/longevity bets (e.g., portfolio overlaps with Seed Health-adjacent consumer health themes).

Others

• Allen & Company: Private investment bank and venture investor with historic exposure to media, tech, and science-enabled companies. Adjacent rather than directly competitive, but historically a peer for visionary founders in tech/biology frontier plays.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/artisventures
• LinkedInlinkedin.com/company/artis-ventures
• Facebookfacebook.com/399591270124690

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments169 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Artis Ventures